APIs and radiopharmaceutical CDMO services

With permission in the use of radionuclides, Huayi Technology can provide customers with an open technology platform from pre-clinical process development to commercial production of radiopharmaceutical APIs and intermediates.

We can provide you with a wide range of services including synthetic route development, process development and optimization, scale-up production, registration and validation batch production, and commercial production. Our pharmaceutical manufacturing facilities are capable of meeting the labeling needs of a wide range of radionuclides.

——Services

——Integrated network for manufacturing and distribution in China

Huayi is investing in the construction of a leading radiopharmaceutical production base, covering the whole industry chain of production, sales and distribution. The goal is to establish a nuclear medicine production and distribution network covering more than 85% of the Chinese population.

PET Precursor R&D Center

Huayi PET Precursor R&D Center is well-equipped, including liquid chromatography, gas chromatography, inductively coupled plasma mass spectrometry, nuclear magnetic resonance analyzer, liquid chromatography-mass spectrometry coupling, FTIR, UV scanning and other instruments. We have experienced chemical synthesis experts, chemical separation experts, researchers with Ph.D. and M.S. degrees to provide comprehensive technical support

Radiolabeling

Huayi Technology has a full range of radionuclide use permission, and the site is equipped with cyclotron, synthesis hot cell and multiple R&D synthesis modules. Through the use of ¹⁸F, ⁶⁸Ga, ⁶⁴Cu and other positron isotopes for compound labeling (such as: small molecule compounds, peptides, proteins, large molecule compounds, nanomaterials, antibodies, etc.), and can be prepared, separated and purified after labeling to achieve the required specific activity and radiochemical purity.